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http://dx.doi.org/10.1016/j.stemcr.2016.08.006SUMMARYHow mutations in the microtubule-associated protein tau (MAPT) gene cause frontotemporal dementia (FTD) remains poorly under-
stood. We generated and characterized multiple induced pluripotent stem cell (iPSC) lines from patients with MAPT IVS10+16 and
tau-A152T mutations and a control subject. In cortical neurons differentiated from these and other published iPSC lines, we found
that MAPT mutations do not affect neuronal differentiation but increase the 4R/3R tau ratio. Patient neurons had significantly higher
levels ofMMP-9 andMMP-2 andweremore sensitive to stress-induced cell death. Inhibitors ofMMP-9/MMP-2 protected patient neurons
from stress-induced cell death and recombinant MMP-9/MMP-2 were sufficient to decrease neuronal survival. In tau-A152T neurons,
inhibition of the ERK pathway decreased MMP-9 expression. Moreover, ectopic expression of 4R but not 3R tau-A152T in HEK293 cells
increasedMMP-9 expression and ERK phosphorylation. These findings provide insights into themolecular pathogenesis of FTD and sug-
gest a potential therapeutic target for FTD with MAPTmutations.INTRODUCTION
Frontotemporal dementia (FTD), the second most com-
mon form of presenile dementia, often causes changes in
personality and behavior (Boxer and Miller, 2005). There
is no effective treatment, and the molecular pathogenic
mechanisms are poorly understood (Roberson, 2012; Irwin
et al., 2015). Mutations in the gene encoding the microtu-
bule-associated protein tau (MAPT) are responsible for a
substantial fraction of FTD cases (Hutton et al., 1998; Loy
et al., 2014). Tau pathology is also a hallmark of Alzheimer’s
disease (AD), and its pathogenic roles and utility as a poten-
tial drug target in AD have been extensively investigated
(Wang and Mandelkow, 2016; Yoshiyama et al., 2013).
Tau helps assemble and stabilize microtubules. In the
CNS, several isoforms of tau are produced from a single
gene by alternative splicing (Goedert et al., 1989). More
than 40 pathogenic MAPTmutations have been described
in more than 100 families with FTD (Cruts et al., 2012; Alz-
heimer Disease & Frontotemporal Dementia Mutation
Database, http://www.molgen.vib-ua.be/FTDMutations).
Many MAPT mutations are either missense mutations or
small deletions in the coding region or in introns, which
can affect alternative splicing (e.g., of exon 10) (Hutton
et al., 1998; Niblock and Gallo, 2012). Tau also modulates
signaling cascades by acting as scaffolding proteins for316 Stem Cell Reports j Vol. 7 j 316–324 j September 13, 2016 j ª 2016 The
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may also affect other cellular functions (Ittner et al.,
2010; Morris et al., 2011).
Many studies of tau toxicity have used cellular or animal
models in which wild-type (WT) or mutant tau is ectopi-
cally overexpressed (Morris et al., 2011; Wittmann et al.,
2001). Patient-specific induced pluripotent stem cells
(iPSCs) are an exciting alternative approach to study dis-
ease genes in their native genetic context (Yamanaka,
2007) and uncover novel pathogenic mechanisms in AD,
Parkinson’s disease, FTD, and other neurodegenerative dis-
orders (Israel et al., 2012; Soldner et al., 2009; Almeida et al.,
2012). Here we generated and characterized multiple iPSC
lines from an FTD patient with a MAPT IVS10+16 muta-
tion, an FTDpatient with the tau-A152T variant, and a con-
trol subject. The MAPT IVS10+16 mutation is relatively
common and found inmany families in different countries
(Hutton et al., 1998; Janssen et al., 2002). The tau-A152T
variant has been shown to significantly increase the risk
for both FTD and AD (Coppola et al., 2012; Kara et al.,
2012) and induce aggregation-independent toxicity (Pir
et al., 2016). To study their pathogenic mechanisms, we
differentiated these newly generated iPSC lines, as well as
published control and tau-A152T lines (Almeida et al.,
2012; Fong et al., 2013) into postmitotic cortical neurons
and identified upregulation of matrix metalloproteinase 9Author(s).
ecommons.org/licenses/by-nc-nd/4.0/).
(MMP-9) through the ERK pathway as an important path-
ogenic mechanism in FTD with MAPTmutations.RESULTS
Generation of Patient-Specific iPSC Lines withMAPT
Mutations
To understand how endogenously expressed mutant tau
contributes to eventual neurodegeneration, we obtained
skin biopsies from two patients with MAPT mutations
and a healthy control subject. Patient 1 was a male with a
tau-A152T variant. The patient’s clinical history and neuro-
logic examination were consistent with a diagnosis of pro-
gressive supranuclear palsy (PSP). Patient 2 was amale with
anMAPT IVS10+16 mutation whose clinical diagnosis was
largely normal at the time of skin biopsy but developed
FTD later on. The control subject is a female familymember
of patient 2. Putative iPSC lineswere derived from the fibro-
blasts as described previously (Yamanaka, 2007; Almeida
et al., 2012), and 10–15 putative iPSC lines from each sub-
ject were extensively characterized. Immunocytochemistry
analysis showed expression of stem cell makers such as
OCT4, SSEA4, NANOG, TRA1-60, and TRA1-81 in all
selected iPSC lines (Figure S1A). qRT-PCR showed that total
and endogenous expression levels of the four reprogram-
ming factors were the same in each line, confirming
silencing of the transgene (Figure S1B). The iPSC lines
had normal karyotypes (Figure S1C), and selected lines
could differentiate into cell types of all three germ layers,
confirming their pluripotency (Figure S1D). Based on these
characterizations, we selected iPSC lines 3L1 of control 1,
19L3 and 19L4 of patient 1, and 3L6 and 3L9 of patient 2
for further study. In addition to the lines generated in our
current study, we also used two published control iPSC
lines, 2L17 and 2L20, derived from a male (Almeida et al.,
2012), and one published iPSC line from another tau-
A152T mutation male carrier (Fong et al., 2013).MAPTMutations Do Not Affect Early Neuronal
Differentiation
At passages 25–30, all fully reprogrammed control and pa-
tient iPSC lineswere differentiated into postmitotic cortical
neurons as described (Figure 1A) (Almeida et al., 2012). Four
weeks after terminal differentiation, 80% of cells were pos-
itive for theneuron-specificmarkerMAP2, and therewasno
significant difference between control and patient neurons
(Figure S2A). The percentages of VGLUT1-positive excit-
atory and GABA-positive inhibitory neurons were similar
inneuronal cultures differentiated fromcontrol andpatient
iPSCs (Figures S2B and S2C).Moreover, the total expression
levels of tau andPSD-95were the same in 1-month-oldneu-
rons derived from control and patient iPSCs (Figure 1B).To further characterize differentiated human cortical
neurons, we performed whole-cell voltage-clamp re-
cordings. Tetrodotoxin-sensitive action potentials were
induced in 64% of control neurons, 78% of tau-A152T
neurons, and 78% of MAPT IVS10+16 neurons (9–11 cells
were recorded for each group, Figure 1C). The resting
membrane potential did not differ among neurons differ-
entiated from all iPSC lines (Figure S2D). Functional
synaptic connections formed in these cell lines, as shown
by a-amino-3-hydroxy-5-methyl-4-isoxazole propionate
(AMPA)-type glutamate receptor-mediated spontaneous
excitatory postsynaptic currents (sEPSCs) that could be
blocked with (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]
quinoxaline-2,3-dione (NBQX) (Figure 1D). The mean
amplitude, frequency, rise time, and decay time constant
of sEPSCs were indistinguishable in all lines (Figures
S2E–S2H). Thus, both molecular and electrophysiological
analyses suggest MAPT mutations do not affect early
neuronal differentiation. Therefore, any disease-relevant
phenotypes would unlikely be due to changes in neuronal
subtypes.
MAPTMutations Increase the Level and Activity of
Secreted MMP-9 and MMP-2
MMPs, a family of Zn-containing proteolytic enzymes,
modulate both normal development and human patho-
physiology. MMP-9 directly cleaves Huntingtin protein in
Huntington’s disease, a progressive neurodegenerative dis-
order (Miller et al., 2010). Moreover, dysregulation of
MMP-9 in the CNS is a cause of neuronal developmental
disorders (Reinhard et al., 2015). Thus, we set out to
examine MMP-9 production in control and patient neu-
rons with MAPT mutations. To this end, we performed
zymography as described previously (Biswas et al., 2010),
which measures the level and total activity of MMP-9.
Tau-A152T neurons had >10-fold higher level and activity
of secreted MMP-9 than control neurons (Figures 2A and
2B), as didMAPT IVS10+16 neurons to a lesser extent (Fig-
ures 2C and 2D). The total activity of secreted MMP-2 was
more than 2-fold higher in patient-specific neurons than in
controls (Figures 2A–2D). The level of secreted MMP-9 and
MMP-2 was also increased in cortical neurons derived from
a published iPSC line with the tau-A152T mutation (Fong
et al., 2013) (Figures 2E and 2F). The effect on the total level
and activity of secretedMMP-9/MMP-2 seems to be specific
to mutant tau, since in progranulin-deficient FTD cortical
neurons, there was no significant change in secreted
MMP-2 level (Figure S2I) and the secreted MMP-9 level
was below detection as in control neurons (not shown).
This increase is likely in part due to transcriptional regula-
tion, since the mRNA levels of MMP-9 and MMP-2 in tau-
A152T and MAPT IVS10+16 neurons were higher than in
control neurons (Figure S2J).Stem Cell Reports j Vol. 7 j 316–324 j September 13, 2016 317
Figure 1. Differentiation and Characterization of Cortical Neurons Derived from iPSC Lines from FTD Patients and Control Subjects
(A) Phase-contrast images of neurospheres (upper), differentiated neurons (middle), and MAP-2 immunostaining of neurons (lower) from
the iPSC lines. Scale bars, 50 mm.
(B) Western blot analysis of MAP-2, PSD-95, and tau-expression levels in 4-week-old neurons differentiated from iPSC lines. Actin served as
the loading control.
(C) Representative action potentials elicited by current injection (0–400 pA in 100-pA steps) and blocked by tetrodotoxin (TTX) of lines
3L1 of control 1, 19L3 of patient 1, and 3L6 of patient 2. Nine to eleven cells were recorded for each group.
(D) iPSC-derived neurons (n = 7 per subject) displayed synaptic responses and were sensitive to the AMPA receptor antagonist NBQX.
(E) Averaged sEPSC events from neurons of different subjects.
See also Figures S1 and S2.Elevated Extracellular MMP-9 and MMP-2 Contribute
to Neuronal Cell Death of iPSC-Derived Human
Cortical Neurons withMAPTMutations
The increased extracellular MMP-9 and MMP-2 activity in
FTD patient-specific cortical neurons suggests that these
molecular changes may contribute to disease phenotypes.
To investigate this possibility, we first examined the relative
survival of human cortical neurons derived from control
subjects of patients with MAPT mutations without any
inducers of cellular stress. We found that, indeed, TUJ1+
neurons showed reduced survival as measured by TUNEL
analysis (Figure 3A). Interestingly, we did not observe318 Stem Cell Reports j Vol. 7 j 316–324 j September 13, 2016TUNEL labeling in more than 100 glial cells (Figure S3A),
suggesting glial cells are less vulnerable to increased
MMP-9 and MMP-2 levels. We then examined the sensi-
tivity of iPSC-derived human cortical neurons to different
inducers of cellular stress. We treated these neurons with
staurosporine, a broad-spectrum kinase inhibitor that in-
duces apoptosis (Budd et al., 2000); rotenone, a complex I
inhibitor that induces mitochondrial dysfunction (Sherer
et al., 2003); and rapamycin, an inhibitor of the mamma-
lian target of the rapamycin (mTOR) signaling pathway
with many downstream effects (Li et al., 2014). When
measuring cell viability using the MTT assay, we found
Figure 2. MMP-9 and MMP-2 Expression Is Increased in Human Neurons with MAPT Mutations
(A) Zymographic analysis of secreted MMP-9 and MMP-2 in conditioned media from tau-A152T human neurons (patient 1). Immuno-
blotting of cell lysates with actin served as the loading control.
(B) Quantification of secreted MMP-9 and MMP-2 in (A). Values are mean ± SD of three independent experiments. p < 0.001 by Student’s
t test.
(C) Zymographic analysis of the level of secreted MMP-9 and MMP-2 in conditioned media from MAPT IVS10+16 human neurons (patient 2).
Immunoblotting of cell lysates with actin served as the loading control.
(D) Quantification of secreted MMP-9 and MMP-2 in C. Values are mean ± SD of three independent experiments. p < 0.01 by Student’s t test.
(E) Zymographic analysis for MMP-9 and MMP-2 in conditioned media from tau-A152T human neurons (patient 3; Fong et al., 2013).
Immunoblotting of cell lysates with actin served as the loading control.
(F) Quantification of MMP-2 and MMP-9 levels in (E) based on three experiments. Values are mean ± SD of three experiments. ***p < 0.001
by Student’s t test.
See also Figure S3.that patient-specific neurons are more sensitive than con-
trol neurons to cell death induced by rapamycin (Figure 3B)
but not by staurosporine or rotenone (Figures S3B and
S3C), suggesting compromised function in the mTOR
pathway or related molecular pathways. For this experi-
ment, we compared relative survival of neurons derived
from the same iPSC line with or without the treatment
with inducers of cellular stress; thus, the value from theMTT assay without stressors for each line was always taken
as 100%.
To examine the contribution of MMP-9 and MMP-2 to
reduced survival of iPSC-derived cortical neurons with
MAPT mutations, we quantified their mRNA levels in
iPSC-derived 4-week-old human neurons treated with ra-
pamycin for an additional 3 days. MMP-9/MMP-2 mRNA
levels in tau-A152T and MAPT IVS10+16 neurons wereStem Cell Reports j Vol. 7 j 316–324 j September 13, 2016 319
Figure 3. Increased MMP-9 and MMP-2 Expression Contributes to Neurodegeneration of Patient Neurons under Stress
(A) TUNEL analysis of TUJ1+ 4-week-old cortical neurons from controls and tau patients under basal conditions. Values are mean ± SD of
two independent experiments and in each experiment, 100 cells were counted for each iPSC line.
(B) Percentage of human neuron survival after 48 hr of treatment with DMSO, 40 nM rapamycin, or 40 nM rapamycin and inhibitors (Inh) of
MMP-2 (5 mM) and MMP-9 (200 nM). Values are mean ± SD from three independent experiments.
(C) qRT-PCR analysis of MMP-2 and MMP-9 mRNA levels in human neurons after treatment with DMSO or 40 nM rapamycin (Rap). Values are
mean ± SD from three independent experiments.
(D) Survival of 4-week-old control human neurons 48 hr after treatment with recombinant MMP-2 (5 mg/mL) and MMP-9 (5 mg/mL). Values
are mean ± SD of three independent experiments.
Statistical significance is indicated by p values and was determined by Student’s t test. See also Figure S3.significantly higher than that in control neurons (Fig-
ure S2J), and rapamycin increased these levels (p < 0.01)
(Figure 3C). Human neurons differentiated from iPSCs
are difficult to transfect at high efficiency. To examine
the contributions of increased MMP-9 and MMP-2 to
neuronal cell death, we used two compounds that are
known to inhibit MMP-9 and MMP-2 activity (catalog
#444278 and #444244, Calbiochem). We found that this
treatment partially rescued the increased sensitivity to ra-
pamycin and improved survival (Figure 3B). Furthermore,
treatment with recombinant MMP-9/MMP-2 induced
neuronal cell death in 4-weeek-old postmitotic cortical
neurons differentiated from iPSCs of a healthy control
subject, as measured by MTT assay (Figure 3D). MMP-2
and MMP-9 seem to induce cell death directly, since this320 Stem Cell Reports j Vol. 7 j 316–324 j September 13, 2016treatment also increased the TUNEL signal in iPSC-derived
neurons (Figures S3D and S3E). These results suggest that
elevated extracellular MMP-9 and MMP-2 are sufficient
to cause neuronal cell death in human neurons. Taken
together, our data suggest that elevated level and activity
of extracellular MMP-9 and MMP-2 are in part responsible
for the observed loss of patient neurons under rapamycin-
induced stress.
4R Tau-A152T Activates the ERK Pathway to Increase
MMP-9 Expression
It is known that MMP-9 expression is regulated by ERK
(Wang et al., 2006). Therefore, to explore the mechanism
by which mutant tau increases MMP-9 production in
iPSC-derived patient neurons with MAPT mutations, we
Figure 4. The tau-A152T Mutation In-
creases MMP-9 Expression through Ef-
fects on ERK
(A) Western blot analysis of ERK and p-ERK
in 4-week-old iPSC-derived human cortical
neurons.
(B and C) Neurons from line 3 of patient 1
(B) and line 6 of patient 2 (C) were treated
with DMSO or the MEK inhibitor PD98059.
Cell lysates were analyzed by western blot
with antibodies against p-ERK, ERK, and
actin, and conditioned media were analyzed
by zymography for MMP-9 and MMP-2. The
numbers indicate the levels of MMP-9 rela-
tive to actin.
(D) Western blot analysis of tau levels in
HEK293 cells transfected with human 4R WT
or 4R tau-A152T.
(E) Zymographic analysis of secreted MMP-9
and MMP-2 in conditioned media, and
western blot analysis of actin, p-ERK, and
ERK levels in respective lysates from HEK293
cells expressing 4R WT or 4R tau-A152T.
(F) qRT-PCR analysis of the expression
levels of MMP-2 and MMP-9 mRNA in HEK293
cells expressing 4R WT or 4R tau-A152T.
Values are mean ± SD from three indepen-
dent experiments. ***p < 0.001 by Stu-
dent’s t test.first examined ERK-pathway activity. The level of phos-
phorylated ERK (p-ERK) was significantly increased in
tau-A152T neurons and to a lesser extent in MAPT
IVS10+16 patient neurons (Figure 4A). It is worth noting
that the level and activity of secreted MMP-9 in tau-
A152T neurons is also substantially higher than that in
MAPT IVS10+16 neurons (Figure 2). ERK phosphorylation
in MAPT mutant neurons was blocked by treatment with
PD98059, a specific inhibitor of MEK-mediated activation
of ERK (Li et al., 2001) (Figures 4B and 4C). Correspond-
ingly, the level and activity of secreted MMP-9 was greatly
suppressed in both tau-A152T andMAPT IVS10+16 patient
neurons (Figures 4B and 4C), suggesting that MMP-9
expression is regulated by the ERK signaling pathway in
cortical neurons. To further confirm the regulation of
MMP-9 by ERK activation, we treated cortical neurons of
both patient 1 and patient 2 with lower concentrations
of PD98059. We found the level and activity of secreted
MMP-9 to correlate well with the extent of ERK phosphor-
ylation (Figure S4A). Interestingly, the level and activity of
MMP-2 was not affected after the PD98059 treatment intau-A152T neurons (Figure 4B) and MAPT IVS10+16 neu-
rons (Figure 4C). These results suggest that FTD-causing
MAPTmutations increase MMP-9 through ERK activation,
while the molecular regulation of MMP-2 induction in pa-
tient neurons remains to be identified.
To further confirm the role of mutant tau in MMP-9 pro-
duction, we first examined the 4R/3R tau ratio in iPSC-
derived patient neurons. As expected, the 4R/3R tau ratio
is greatly increased inMAPT IVS10+16 neurons (Figure S3F)
but not inGRNmutant neurons (Figure S3G). Interestingly,
this ratio is also increased, but to a lesser extent, in tau-
A152T neurons (Figure S3F). We then transfected HEK293
cells, which do not normally express tau, with either 3R
or 4R WT tau or tau-A152T. 4R WT and 4R tau-A152T
were expressed at comparable levels, as shown by western
blot (Figure 4D). However, the secreted MMP-9 level and
activity in conditioned medium was significantly higher
in cultures of cells expressing tau-A152T than WT tau (Fig-
ure 4E). The MMP-9 mRNA level was also higher in cells
expressing tau-A152T (Figure 4F). Correspondingly, the
level of p-ERK was also elevated in HEK293 cells expressingStem Cell Reports j Vol. 7 j 316–324 j September 13, 2016 321
tau-A152T (Figure 4E). Interestingly, the level and activity
of secreted MMP-9 in HEK293 cells expressing WT 3R tau
and 3R tau-A152T are similar (Figures S4B and S4C). ERK
phosphorylation is also not affected by A152T mutation
in 3R tau (Figure S4D). Taken together, these findings
strongly suggest that 4R tau-A152T activates the ERK
pathway more strongly, which in turn increases the level
and activity of secreted MMP-9. 4R tau-A152T expression
(Figures 4E and 4F) but not inhibition of ERK activity (Fig-
ures 4B and 4C) also increases the total activity of secreted
MMP-2, suggesting that tau-A152T increases the level and
activity of secreted MMP-2, likely through an ERK-inde-
pendent pathway.DISCUSSION
In this study, we found a significant increase in the level
and activity of secretedMMP-9 andMMP-2 in cortical neu-
rons derived from iPSCs of three subjects withMAPTmuta-
tions. More importantly, this increase contributed to
neuronal cell loss induced by cellular stress, and inhibition
ofMMP-9/MMP-2 activity was neuroprotective. Our results
are consistent with a recent paper published during our
study in which the authors showed that MMP-9 is specif-
ically expressed in fast motor neurons and contributes to
selective neuronal vulnerability in amyotrophic lateral
sclerosis (ALS) (Kaplan et al., 2014). Moreover, reduction
of MMP-9 through genetic or pharmacological approaches
delayed muscle denervation in vivo (Kaplan et al., 2014).
Thus, MMP-9 is a potential therapeutic target for both
FTD and ALS, although how MMP-9 induces cell death in
iPSC-derived cortical neurons remains to be determined
at a mechanistic level.
Our studies also provide mechanistic insight into the
increased level and activity of secreted MMP-9 in cortical
neurons derived from FTD patient-specific iPSCs with
MAPT mutations. The increase seems to be mediated by
ERK-pathway activation. Indeed, ectopic expression of
mutant 4R but not 3R tau in HEK293 cells resulted in
ERK phosphorylation and increased MMP-9 production.
However, the molecular pathways of MMP-2 induction
remain to be further delineated. These results further sup-
port the notion that tau is not only a key substrate for
phosphorylation but also functions upstream of several ki-
nase signaling pathways (Ittner et al., 2010; Morris et al.,
2011; Vossel et al., 2015). Our iPSC lines with different
MAPT mutations will be useful for further investigations
of the roles of endogenous tau in cell signaling and
neuronal vulnerability, such as in an accompanying paper
by Silva et al. (2016). In the future, it will be useful to
generate isogenic iPSC lines with different MAPT muta-
tions and confirm the effect of endogenous mutant tau322 Stem Cell Reports j Vol. 7 j 316–324 j September 13, 2016on the ERK-MMP-9 pathway. Moreover, since different
tau strains with prion-like properties cause different tauo-
pathies in vitro and in vivo (Sanders et al., 2014), it will
be also interesting to determine which tau strains are pre-
sent in iPSC-derived human neurons and activate the ERK
pathway.EXPERIMENTAL PROCEDURES
Isolation of Primary Human Skin Fibroblasts and
Generation of iPSCs
Skin biopsies were obtained from two patients with MAPT muta-
tion. Patient 1 was a 68-year-old man with a 6-year history of per-
sonality changes and cognitive and speech deterioration. He was
diagnosed with PSP and has a tau-A152T mutation. Patient 2 was
presymptomatic at the time of skin biopsy but had an extensive
family history of FTD and has a MAPT IVS10+16 mutation.
iPSCs were generated as described by Almeida et al. (2012). In
brief, fibroblasts were transduced for 7 days with equal volumes
of supernatant from retroviruses expressing human OCT3/4,
SOX2, KLF4, and c-MYC and seeded onto mitomycin C-treated
SNL feeder cells. Five weeks after viral transduction, individual col-
onies were picked and transferred to 12-well plates containing
feeder cells for expansion. Well-established iPSC lines were adapt-
ed to feeder-free conditions andmaintainedwithmTeSR1medium
(STEMCELL Technologies) on Matrigel (BD Biosciences).
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